Business
MustGrow Announces Record Q3-2025 Results
Investor Webcast: Wednesday, November 26th at 4:00pm ET / 1:00pm PT . Register/View Here: http...
About this update from Mustgrow Biologics Corp.
[{"type":"text","content":"MustGrow Announces Record Q3-2025 ResultsInvestor Webcast: Wednesday, November 26th at 4:00pm ET / 1:00pm PT.Register/View Here: https://us02web.zoom.us/webinar/register/8617635107958/WN_Ka6aNlTZTLuCJPaetQoLuQ.Please join/register at least 5 minutes prior to the call.Questions emailed to [email protected] will be addressed during the Q&A portion of the webcast.Saskatoon, Saskatchewan--(Newsfile Corp. - November 25, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the \"Company\" or \"MustGrow\"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended September 30, 2025. For complete details, please refer to the Q3-2025 Condensed Interim Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.Key Financial Highlights:Sales revenue of $0.8 million was recorded in Q3-2025 vs. no revenue in Q3-2024Gross profit of $180,555 equating to a 22.9% gross profit margin in Q3-2025 (up from 20.9% in Q2-2025)(1)Cash and equivalents on hand as at September 30, 2025 was $3.3 million with inventory of $1.9 million\"The third calendar quarter is typically the lowest product revenue 'shoulder season' for Canadian agriculture as farmers are harvesting their crops rather than purchasing input products. MustGrow's gross profit margin improvement over the second quarter resulted from higher margin product sales through our Canadian sales and distribution division, NexusBioAg,\" stated Corey Giasson, President and CEO of MustGrow. \"As mentioned in previous earnings calls, Q1 and Q4 are traditionally stronger sales periods, as Canadian farmers purchase crop inputs. We are looking forward to a strong finish to the year in Q4 and also Q1-2026 as farmers purchase products in preparation for the 2026 growing season.\"The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S. Notes:1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measurin...